News
Roche scores EU approval for at-home SMA treatment Evrysdi
The European Commission (EC) has approved Roche’s spinal muscular atrophy (SMA) treatment Evrysdi for use in patients aged two months and older.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The European Commission (EC) has approved Roche’s spinal muscular atrophy (SMA) treatment Evrysdi for use in patients aged two months and older.